EU and US could reach trade deal this weekend - Reuters
Catherine T. Doherty, Executive Vice President of Regional Businesses at Quest Diagnostics Inc. (NYSE:DGX), has recently reported a sale of company stock. According to a Form 4 filing with the Securities and Exchange Commission, Doherty sold 716 shares on March 4, 2025, at a price of $175.79 per share, totaling $125,865. This transaction was carried out under a prearranged Rule 10b5-1 sales plan. The sale comes as Quest Diagnostics, with a market capitalization of $19 billion, trades near its 52-week high of $178.09. InvestingPro analysis indicates the stock is currently trading above its Fair Value.
In addition to the sale, Doherty reported several other transactions. On March 3, 2025, she disposed of 394 shares at $173.74 per share to cover tax withholding obligations, and on March 4, 2025, she acquired 10,380 shares at the same price as part of a settlement for a performance share award. Furthermore, 5,010 shares were disposed of to cover tax obligations related to the performance stock award settlement. After these transactions, Doherty now holds 73,438 shares directly and 4,427 shares indirectly through a 401(k) and Supplemental Deferred Compensation Plan. Quest Diagnostics maintains strong financial health with a "GOOD" overall score from InvestingPro, which offers comprehensive analysis including 8+ additional ProTips and a detailed Pro Research Report for deeper insights into the company’s performance and outlook.
In other recent news, Quest Diagnostics reported its fourth-quarter 2024 financial results, exceeding market expectations. The company achieved an adjusted earnings per share (EPS) of $2.23, surpassing the forecast of $2.19, and reported revenues of $2.62 billion, which also exceeded projections. Quest Diagnostics experienced a 14.5% year-over-year increase in consolidated revenues, driven by strong performance in advanced diagnostics and preventative health services. In related developments, JPMorgan raised the company’s price target to $180, maintaining a Neutral rating, following the robust earnings report. JPMorgan highlighted Quest Diagnostics’ solid clinical lab operations and adjusted their revenue forecast for 2025 to $10.776 billion. Meanwhile, Citi downgraded Quest Diagnostics from Buy to Neutral, citing concerns over margin pressures and earnings growth prospects, setting a new price target of $185. This downgrade reflects anticipated challenges from margin headwinds and dilution from new initiatives. As Quest Diagnostics continues to navigate these dynamics, investors and stakeholders will be closely watching the company’s strategic initiatives and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.